The association between acute myeloid leukaemia (AML) and the aberrant expression of Hoxa9 is evidenced by (1) proviral activation of Hoxa9 and Meis1 in BXH-2 murine AML, (2) formation of the chimeric Nup98-HoxA9 transactivator protein as a consequence of the t(7;11) translocation in human AML, and (3) the strong expression of HoxA9 and Meis1 in human AML. In mouse models, enforced retroviral expression of Hoxa9 alone in marrow is not sufficient to cause rapid AML, while co-expression of Meis1 and Hoxa9 induces rapid AML. In contrast, retroviral expression of Nup98-HoxA9 is sufficient to cause rapid AML in the absence of enforced Meis1 expression. Previously, we demonstrated that Hoxa9 could block the differentiation of murine marrow progenitors cultured in granulocytemacrophage colony-simulating factor (GM -CSF). These progenitors lacked Meis1 expression, could not proliferate in stem cell factor (SCF), but could differentiate into neutrophils when switched into granulocyte colonysimulating factor (G-CSF). Ectopic expression of Meis1 in these Hoxa9 cells suppressed their G-CSF-induced differentiation, permitted proliferation in SCF, and therein offered a potential explanation of cooperative function. Because Meis1 binds N-terminal Hoxa9 sequences that are replaced by Nup98, we hypothesized that Nup98-HoxA9 might consolidate the biochemical functions of both Hoxa9 and Meis1 on target gene promoters and might evoke their same lymphokineresponsive profile in immortalized progenitors. Here we report that Nup98-HoxA9, indeed mimicks Hoxa9 plus Meis1 coexpression -it immortalizes myeloid progenitors, prevents differentiation in response to GM -CSF, IL-3, G-CSF, and permits proliferation in SCF. Unexpectedly, however, Nup98-Hoxa9 also enforced strong transcription of the cellular Hoxa9, Hoxa7 and Meis1 genes at levels similar to those found in mouse AML's generated by proviral activation of Hoxa9 and Meis1. Using Hoxa9 7/7 marrow, we demonstrate that expression of Hoxa9 is not required for myeloid immortalization by Nup98-HoxA9. Rapid leukaemogen-
Introduction
HoxA9 behaves as an oncogene in leukaemia following mutations that induce its persistent expression or that convert it into a persistent transcriptional activator. Spontaneous myeloid leukaemia in BXH-2 mice is accompanied by proviral integrations that activate transcription of Meis1 and either Hoxa9 or Hoxa7 (Nakamura et al., 1996a; Moskow et al., 1995) . Enforced expression of Hoxa9 and Meis1a in mice induces AML after a short latency (3 months), while expression of Hoxa9 alone induces AML only after a long latency (8 months) and expression of Meis1 alone does not cause disease (Kroon et al., 1998) . The observation that HoxA9, HoxA7, and Meis1 are normally expressed in early, self-renewing human CD34+ progenitors and downregulated during differentiation Kawagoe et al., 1999) and expressed strongly in most human AML (Golub et al., 1999) suggests a relationship between self-renewal and the functions of HoxA9, HoxA7 and Meis1. In support of this relationship are the observations that Hoxa9 null mice have reduced levels of myeloid and Blymphoid precursors and that enforced expression of Hoxa9 suppresses differentiation and maintains myeloid progenitor self-renewal in IL-3 or GM -CSF (Calvo et al., 2000; Schnabel et al., 2000) . Thus, one normal function of Hoxa9 in vivo might be to maintain progenitor self-renewal by restricting differentiation, yet permitting proliferation in response to certain environmental factors. Myeloid progenitors immortalized in vitro by HoxA9 exhibit specific differentiation characteristics -they become neutrophils in response to G-CSF (Calvo et al., 2000) , macrophages in response to M-CSF (Calvo et al., 2000) , and they die in the presence of SCF despite the fact that they express cell surface c-Kit (SCF-R, CD117; Calvo et al., 2001) . Meis1 alters the differentiation of Hoxa9-immortalized cells by suppressing their G-CSF-induced granulocytic differentiation and by allowing them to proliferate in response to SCF (Calvo et al., 2001) . These novel Meis1 functions are proposed to cooperate with Hoxa9 to promote leukaemic potential (Calvo et al., 2001) . Intriguingly, HoxA9, HoxA7 and Meis1 are also expressed persistently in the vast majority of human AML (Kawagoe et al., 1999; Golub et al., 1999) , raising the question of whether human myeloid oncoproteins directly activate or indirectly maintain transcription of these homeobox genes as a means of suppressing differentiation and maintaining self-renewal.
The t(7;11)(p15;p15) translocation forms Nup98-HoxA9, a chimeric oncoprotein that contains a cryptic transcriptional activation domain encoded by Nucleoporin 98 fused to Hoxa9 sequences that encodes both a DNA-binding homeodomain (HD) and a short ANWL motif N-terminal to the HD that binds the Pbx family of transcriptional cofactors ( Figure 1 ; Nakamura et al., 1996b; Borrow et al., 1996) . Nup98-HoxA9 is found in de novo and therapy-related AML and in myelodysplastic syndromes Nishiyama et al., 1999) , as well as in the blast crisis phase of chronic myelogenous leukaemia (Ahuja et al., 2001; Yamamoto et al., 2000) , suggesting that a principal oncogenic function of Nup98-HoxA9, like Hoxa9, is to prevent myeloid differentiation. In mice, Nup98-HoxA9 induces a rapid, polyclonal, myeloproliferative disease that progresses to clonal AML, but this disease progression, unlike that initiated by HoxA9, is only weakly complemented by enforced retroviral expression of Meis1 (Kroon et al., 2001) . The transforming properties of Nup98-HoxA9, therefore, are stronger than those of Hoxa9, do not cooperate significantly with Meis1, and are similar to the combined properties of Hoxa9 and Meis1 in terms of disease latency.
Because Meis1 binds N-terminal Hoxa9 sequences that are eliminated by fusion with Nup98 ( Figure 1 ; Shen et al., 1997) , one hypothesis to explain the stronger transforming function of Nup98-HoxA9 is that it consolidates -within a single oncoproteinthe collective biochemical functions of Hoxa9 and Meis1. As Nup98-HoxA9 contains a Pbx-interaction motif required for its ability to transform fibroblasts (Kasper et al., 1999) , gene targetting by Nup98-HoxA9 could also involve heterodimerization with endogenous Pbx, which forms both heterodimers and triple complexes with Hoxa9 and Meis proteins (Shen et al., 1999; Shanmugam et al., 1999; Ferretti et al., 2000; Chen and Ruley, 1998; Swift et al., 1998) . Here we report that Nup98-HoxA9 immortalizes myeloid progenitors that mimic those co-expressing Hoxa9 plus Meis1, exhibiting differentiation arrest in response to GM -CSF and G-CSF, as well as proliferation in response to SCF. However, unlike Hoxa9, Nup98-HoxA9 maintained expression of endogenous Hoxa9, Hoxa7 and Meis1 at levels comparable to the oncogenic levels induced by provirus in BXH-2 AML. The same target cell was immortalized by Nup98-HoxA9 in Hoxa9 7/7 marrow. We conclude that Nup98-HoxA9 is unique in its ability to maintain the expression of Meis1 and of multiple Hox genes. It remains unclear, however, whether the cellular functions induced by Nup98-HoxA9 require the functions of downstream Meis1 and Hox proteins.
Results

Nup98-HoxA9 prevents differentiation of factordependent myeloid progenitors and enforces expression of HoxA9
To determine the impact of Nup98-HoxA9 on the cytokine-specific differentiation of primary myeloid progenitors, early progenitors were purified from marrow, expanded in a cytokine cocktail, infected with MSCV-based retrovirus encoding either Neo R or Nup98-HoxA9 plus Neo R and cultured in medium containing either IL-3 or GM -CSF (Calvo et al., 2000) . Progenitors expressing Nup98-HoxA9 yielded rapid outgrowths (within 2 weeks) of factor-dependent progenitors (12 of 12 cultures in IL-3, two of four cultures in GM -CSF; Figure 2G ). In contrast, control cultures infected with Neo R virus yielded slow-growing mast cells in IL-3 (evident only after 4 to 6 weeks), and complete differentiation to neutrophils and monocytes in GM -CSF within 3 weeks. Immunoblot analysis using an antiserum against the homeodomain and Cterminus of Hoxa9 detected Nup98-HoxA9 in each of six immortalized cell lines ( Figure 3A, lanes 4 -9) . Surprisingly, immunoblot samples from Nup98-HoxA9-immortalized progenitors exhibited a second band that comigrated with Hoxa9, and was expressed at a similar abundance as Hoxa9 in M1 myeloid leukaemia cells (lane 1), a myeloid leukaemia containing independent, proviral-induced, transcriptional activation of Hoxa9 plus Meis1 (Nakamura et al., 1996a) . This same band was not found in progenitors immortalized by either E2a-Pbx1 (lane 2) or Hoxb8 (lane 3). Northern blot analysis using 5' Hoxa9 sequences that are eliminated by translocation with Nup98, and therefore do not bind the chimeric Nup98-HoxA9 transcript, verified the selective presence of cellular Hoxa9 transcripts both in M1 cells ( Figure 3B , Figure 3C , lanes 6 -10), while no detectable Hoxa9 was observed in two additional samples of E2a-Pbx1-or Hoxb8-immortalized progenitors (lanes 1 -4). The level of Hoxa9 in Nup98-HoxA9-immortalized progenitors was approximately twice that of M1-AML cells (lanes 5). This analyis predicted that the level of Hoxa9 in Nup98-HoxA9-immortalized progenitors was sufficient to exhibit significant inhibition of myeloid differentiation.
Nup98-HoxA9, but not Hoxa9, enforces transcription of Meis1 and increases Pbx2 abundance
Initially, two populations of Nup98-HoxA9-immortalized progenitors were evaluated for expression of Meis1 ( Figure 3B ). While Hoxa9-immortalized progenitors expressed no Meis1 (lane 6), those immortalized by Nup98-HoxA9 (lanes 8 and 9) expressed Meis1 levels greater than those in M1-AML cells (lane 7), which contain proviral activation of Meis1 transcription. Paralleling this result, antiMeis1 immunoblots demonstrated no Meis1 protein in Hoxa9-immortalized progenitors ( Figure 3D , lane 1), and levels of Meis1 in Nup98-HoxA9-immortalized progenitors (lane 3) that were twice that in M1-AML cells (lane 2) and at least as great as that necessary to prevent G-CSF-induced differentiation and promote the SCF-responsiveness of Hoxa9-immortalized cells (lane 4; sample from cells characterized in Calvo et al., Figure 4 Proliferation responses of progenitors immortalized by Nup98-HoxA9 (filled and unfilled circles) differ dramatically from those immortalized by Hoxa9 (filled squares). Upper row: three cell lines derived in parallel in GM -CSF by immortalization with Nup98-HoxA9 and by Hoxa9 were transferred to the cytokine mixtures designated at the top of each panel. Cell number was quantitiated over 16 days. Lower row: FAX analysis using anti-c-Kit. The identity of each cell population analysed is designated above each plot Figure 5 Morphologic differentiation of Nup98-HoxA9-immortalized progenitors in response to M-CSF is accompanied by expression of the acetyl LDL scavenger receptor. Immunoblot analysis of macrophage acetyl LDL scavenger receptor abundance in myeloid progenitors immortalized by Nup98-HoxA9 (populations 1 and 2; lanes 1 -4), Nup98-HoxA9 AAAA (populations 1 and 2; lanes 5 -8), or Nup98-HoxA9 GGGG (populations 1 and 2; lanes 9 -12) that were cultured in the absence (lanes 1, 3, 5, 7, 9, 11) or in the presence (lanes 2, 4, 6, 8, 10, 12) of M-CSF for 10 days 2001). We conclude that Nup98-HoxA9 maintians levels of Meis1 that are high enough to evoke the leukemic properties of suppressed differentiation in G-CSF and stimulation of SCF-dependent proliferation.
Because Meis stabilizes Pbx proteins, we tested the possibility that progenitors immortalized by Nup98-HoxA9 exhibit increased levels of Pbx2, the major Pbx gene expressed in the myeloid lineage. Using anti-Pbx2-specific immunoblotting (Figure 3E ), the abundance of Pbx2 in six independent populations of progenitors immortalized by Nup98-HoxA9 (lanes 7 -12) was approximtely fivefold greater than that in six different populations of progenitors immortalized by Hoxa9 (lanes 1 -6) . We conclude that Nup98-HoxA9 increases the level of Pbx2, most likely through a mechanism of Meis1-mediated protein stabilization.
Nup98-HoxA9 alters the proliferation and differentiation responses to cytokines int the same manner as coexpressed Hoxa9 and Meis1
In murine myeloid progenitors, Nup98-HoxA9 might block differentiation either through maintaining the independent oncogenic functions of Hoxa9, Meis1a, and other coexpressed Hox genes, or by a mechanism independent of Hoxa9 and Meis1 coexpression. We reasoned that if Nup98-HoxA9 prevented differentiation through Hoxa9 and Meis1, then it should evoke a lymphokine-responsive pattern similar to that induced by coexpression of Hoxa9 and Meis1a -failure of granulocytic differentiation in G-CSF, maintainance of monocytic differentiation in M-CSF, and proliferation in SCF (Calvo et al., 2001) . This phenotype contrasts with that induced by HoxA9 alone, in which immortalized progenitors exhibit rapid granulocytic differentiation in response to G-CSF (Calvo et al., 2000) and fail to proliferate in response to SCF (Calvo et al., 2001) .
Indeed, the lymphokine-responsive proliferation ( Figure 4 ) and differentiation (Figure 2 ) properties of progenitors immortalized by Nup98-HoxA9 differed from those immortalized by Hoxa9 alone, and were virtually identical to those coexpressing Hoxa9 plus Meis1a. Like progenitors immortalized by either Hoxa9 or by coexpression of Hoxa9 and Meis1a, Nup98-HoxA9-immortalized progenitors proliferated indefinitely in GM -CSF or IL-3 (Figure 4 ). Unlike Hoxa9-immortalized progenitors, which differentiate rapidly to neutrophils ( Figure 2C ) and die within 10 days after cultivation in G-CSF (Figure 4 ), Nup98-HoxA9-immortalized cells proliferated indefinitely in G-CSF (Figure 4 ) as a population containing myeloblasts, partially-differentiated myelocytes and completely differentiated neutrophils ( Figure 2I ). This same proliferation accompanied by differentiation is evoked when Meis1 is expressed in Hoxa9-immortalized progenitors (Calvo et al., 2001) . Unlike Hoxa9-immortalized progenitors, which died in SCF ( Figure  4) , those immortalized by Nup98-Hoxa9 proliferated in SCF (Figure 4) as a homogenous population of progenitors ( Figure 2J ) -again similar to progenitors Figure 6 Nup98-HoxA9 enforces expression of Hoxa9, Hoxa7, and Mesi1 despite activation of differentiation genes by GM -CSF and G-CSF. Northern blots containing samples of total RNA derived from cells specified above each panel were probed with cDNA's indicated at upper left corner of each blot. The migration of 18S and 28S RNA, as well as the location of each specific transcript, is indicated at left. Exposure times are indicated at lower right expressing both Hoxa9 and Meis1. This specific mitotic response of Nup98-Hoxa9-immortalized progenitors to SCF was not due to their increased expression of cell surface c-Kit (SCF receptor), as the abundance of c-Kit detected on the surface progenitors immortalized by Hoxa9 or by Nup98-HoxA9 was the same (Figure 4 , lower row). Finally, while addition of SCF to G-CSF promoted expansion of Hoxa9-immortalized progenitors prior to granulocytic differentiation ( Figures 4E  and 2E) , it blocked the residual neutrophilic differentiation evidence by Nup98-HoxA9-immortalized progenitors in G-CSF ( Figure 2K ). In response to M-CSF, progenitors immortalized by Nup98-HoxA9 differentiated into non-mitotic monocytes ( Figure 2L ), similar to those immortalized by either Hoxa9 ( Figure  2F ) or by coexpression of Hoxa9 plus Meis1a (Calvo et al., 2001) , and expressed the macrophage acetyl-LDL scavenger receptor, a monocyte-specific terminal differentiation antigen ( Figure 5, lanes 1 -4) . This analysis demonstrated that Nup98-HoxA9 immortalizes a progenitor capable of either neutrophil or macrophage differentiation, and that their proliferation/differentiation responses to different lymphokines mimic those of progenitors coexpressing Hoxa9 and Meis1.
The Pbx-interaction motif is not required for the ability of Nup98-HoxA9 to immortalize myeloid progenitors or enforce transcription of Hoxa9 and Meis1
Hox proteins regulate gene transcription through mechanisms that are either dependent or independent of Pbx heterodimer partners, and these different mechanisms correspond to the content of Hox-only DNA elements (e.g. TAAT moifs) or Pbx-Hox elements (e.g. TGATTTAT moifs) in target gene promoters. To determine whether Nup98-HoxA9 target genes are coregulated by endogenous Pbx proteins, two mutants encompassing the ANWL Pbx-interaction motif of Hoxa9 were generated, converting the motif to AAAA (denoted Nup98-HoxA9 AAAA ) or to GGGG (denoted Nup98-HoxA9 GGGG ). The effect of each mutant on interaction with Pbx was examined at both the physical and transcriptional levels, and both mutants were tested for their myeloid immortalization properties. By comparison to wild-type Nup98-HoxA9, both mutants failed to heterodimerize with Pbx1 on the Pbx-HoxA9 heterodimer motif TGATTTAT ( Figure  3F , lanes 7 and 8 vs lane 5). While wild-type Nup98-HoxA9 exhibited ninefold cooperative transcription activation with either E2a-Pbx1 or VP16-Pbx1 ( Figure  3G, lane 2 vs lanes 4 and 8) , neither mutant exhibited significant cooperative transactivation (lane 2 vs lanes 5 and 6 or vs lanes 9 and 10). Despite their inability to physically bind or functionally cooperative with Pbx proteins, both Nup98-HoxA9 AAAA and Nup98-HoxA9 GGGG immortalized IL-3-dependent progenitors with the same efficiency and kinetics as did wild-type Nup98-HoxA9 (six of six cultures in each case). Both mutants were expressed at the same level as wild-type Nup98-HoxA9 ( Figure 3A, lanes 10 -15) and induced the expression of endogenous Hoxa9 ( Figure 3A , lanes 10 -15) and of endogenous Meis1 ( Figure 3H , lanes 3 and 4) to a level at least as great as did wild-type Nup98-HoxA9. Progenitors immortalized by either Pbx-interaction mutants of Nup98-HoxA9 responded to lymphokines in the same manner as cells immortalized by wild-type Nup98-HoxA9 (data not shown) and differentiation to macrophages expressing the macrophage acetyl-LDL scavenger receptor in response to M-CSF ( Figure 5 ; lanes 5 -12). We conclude that the genetic targets through which Nup98-HoxA9 mediates both differentiation arrest and enforcement of Hoxa9 and Meis1 transcription are unlikely to require Pbx proteins as heterodimer partners.
Transcription of a subset of Hox and Meis family genes persists in Nup98-Hoxa9-immortalized progenitors despite induction of myeloid differentiation genes by GM -CSF and G-CSF Northern blot analysis was performed on RNA from four different Nup98-HoxA9-immortalized cell lines to quantitate levels of Hox and Meis gene expression ( Figure 6 ). NIH3T3 fibroblasts or progenitors immortalized by Hoxa9 alone were used as positive and negative controls, respectively, for expression of endogenous Meis1. Probing for actin demonstrated equivalent loading of RNA, and hybridization with Nup98 demonstrated similar levels of Nup98-HoxA9 expression in each sample (bottom panels). Transcription of Meis1 was strong (18 h exposure on 15 mg total RNA) while that of Prep1 was weak (70 h exposure). Neither Meis2 nor Meis3 transcripts were detected. A survey of Hox gene expression demonstrated that Hoxa7 was also expressed at levels similar to those of Hoxa9 (Figure 6 ). No expression of Hoxa10, Hoxd4, Hoxb7 and Hoxb8 was detected, even after a 5 day exposure (data not shown). Therefore, Nup98-HoxA9 activates or maintains transcription of a select subset of Hox genes, and, provocatively, this subset contains both of the Hox genes selected by proviral integration to cooperate with Meis1 in BXH-2 mouse leukaemias (Nakamura et al., 1996a) .
To determine whether transcription of Hoxa9, Hoxa7 and Meis1 was passively linked to IL-3 signalling and an immature cell phenotype, rather than actively linked to Nup98-HoxA9 function, we tested whether Hoxa9, Hoxa7 and Meis1 transcription was maintained in GM -CSF, G-CSF and SCF, cytokines that promoted a more differentiated phenotype ( Figure  2) . Cell line no. 4, which was originally derived in IL-3, was shifted to growth in GM -CSF, G-CSF, SCF, GM -CSF plus SCF or G-CSF plus SCF. While genes encoding the myeloid differentiation antigens gp91phox, myeloperoxidase, Ly6G (GR-1), and neutrophil elastase were significantly activated by each cytokine, transcription of Meis1, Hoxa9 and Hoxa7 remained essentially unchanged, linking their transcription to Nup98-HoxA9 function rather than to activation of a specific cytokine receptor activation or simply to an immature cell morphology.
Cellular HOXA9 expression is dispensible for the transforming properties of Nup98-HoxA9
The availability of Hoxa9 7/7 mice allowed us to test the hypothesis that endogenous Hoxa9 functions as an essential subordinate oncoprotein of Nup98-HoxA9. Infection of six primary marrow cultures derived from either Hoxa9 +/+ or Hoxa9 7/7 mice resulted in the rapid outgrowth of IL-3 dependent immortalized cells in both cases ( Figure 7A ). Progenitors immortalized from Hoxa9 7/7 marrow (1) lacked the Hoxa9 band ( Figure 7B ), providing irrefutable proof of its identity as Hoxa9, (2) contained an amount of Nup98-HoxA9 similar to that of progenitors immortalized from Hoxa9 +/+ marrow, suggesting that the efficiency of Nup98-HoxA9 is not compromised in Hoxa9 7/7 marrow, (3) exhibited an abundance of Meis1 protein identical to that found in progenitors immortalized from Hoxa9 +/+ marrow ( Figure 7C ), or (4) maintained the same cytokine-responsive phenotype as Hoxa9 +/+ progenitors immortalized by Nup98-HoxA9 -active proliferation in SCF and failure to differentiate in G-CSF plus SCF ( Figure 7A) . We conclude that endogenous Hoxa9 is not essential for either the morphologic differentiation arrest or the unique cytokine-responsiveness of myeloid progenitors by Nup98-HoxA9.
Nup98-HoxA9 is more stable than HoxA9
The stability of Nup98-HoxA9 and Hoxa9 was measured by quantitating anti-Hoxa9 immunostaining of total lysates from cells treated with cyclohexamide over a 6 h time course. Hoxa9 exhibited a half-life of 35 min, while that of Nup98-HoxA9 was 105 min.
Discussion
Here we demonstrate that Nup98-HoxA9 arrests differentiation of a progenitor capable of neutrophil and monocyte differentiation, enforces transcription of the cellular Hoxa9, Hoxa7 and Meis1 genes, and alters cytokine-specific differentiation and proliferation responses in a manner similiar to that caused by retroviral coexpression of Hoxa9 (suppression of differentiation in response to IL-3 or GM -CSF) and Meis1 (suppression of G-CSF-induced granulocytic differentiation and induction of immortal proliferation in G-CSF and SCF). We demonstrate that the level of Hoxa9 protein in cells immortalized by Nup98-HoxA9 is nearly identical to that in M1 myeloid leukaemia cells, whose oncogenic transformation results from the proviral activation of Hoxa9 and Meis1 transcription (Nakamura et al., 1996a) , and that the levels of Meis1 is the same as that required to prevent G-CSF-induced differentiation and promote SCF-dependent proliferation in Hoxa9-immortalized progenitors. It remains unclear whether Nup98-HoxA9 consolidates the functions of Hoxa9 and Meis1 and immortalizes by a mechanism independent of endogenous Hox and Meis1 proteins, or alternatively functions through multiple subordinate Hox and Meis1 genes to exact the immortalized phenotype. Interestingly, the differentiation of myeloid progenitors blocked by conditional forms of E2a-Pbx1 can be arrested by expression of Hoxa9, but not by expression of Nup98-HoxA9 and Nup98-HoxA9 is also incapable of activating transcription of Hoxa9, Hoxa7 and Meis1 in these cells (data not shown). This result suggests that Nup98-HoxA9 requires the function of at least some subordinate cellular oncogenes whose transcription can be activated by Nup98-HoxA9 only at a specific stage in differentiation.
In mouse models, retroviral expression of Nup98-HoxA9 causes a polyclonal myeloproliferative disease that is much more rapid than myeloid leukaemias induced by expression of Hoxa9 alone, and very similar to the kinetics of myeloid leukaemia induced by coexpression of Hoxa9 plus Meis1 (Kroon et al., 2001) . Our results indicate that the principal function of Nup98-HoxA9 in the CML-like phase of the mouse disease and in the myelodysplastic phase of human AML containing the t(7;11) translocation is to suppress differentiation of myeloid progenitors. Consistent with this prediction, Nup98-HoxA9 arises as a blast crisis event in human CML (Ahuja et al., 2001; Yamamoto et al., 2000) . In mouse AML initiated by Nup98-HoxA9, progression to AML is predicted to require additional mutations that activate proliferation and anti-apoptotic pathways; indeed, half of the AML's that arise in mice as a consequence of retroviral expression of Hoxa9 and Meis1 are factor-independent (Kroon et al., 2001) . Our results suggest that Nup98-Hoxa9 generates a more rapid disease in mice than does Hoxa9 alone because it suppresses G-CSFinduced differentiation and establishes proliferation in response to SCF. The fact that Nup98-HoxA9 evokes a CML-like disease that progresses to AML, while retroviral coexpression of Hoxa9 and Meis1 produces AML without preceding CML-like phase (Kroon et al., 1998) suggests that the ability of Nup98-HoxA9 to arrest differentiation in vivo is weaker than that established by retroviral Hoxa9 and Meis1a coexpression, possibly because it does not enforce as high a level of cellular Hox gene transcription as is achieved using retroviral vectors.
Similar to our observation that Hoxa9 does not require its Pbx-interaction motif to prevent myeloid differentiation (Calvo et al., 2000) , transcription of target genes that mediate immortalization by Nup98-HoxA9 (including Hoxa9, Hoxa7 and Meis1) did not require the function of its Pbx-interaction motif, indicating that these genes are normally regulated by a Pbx-independent mechanism and also suggesting that transcription of Meis1 is under control of Hox proteins. Myeloid immortalization in the absence of the Pbx-interaction motif stands in contrast to fibroblast transformation by Nup98-HoxA9 (Swift et al., 1998) , suggesting that the two transforming mechanisms are fundamentally different. Indeed, by expressing Bcl2 in Nup98-HoxA9-immortalized progenitors and then withdrawing cytokine, we find that Nup98-Hoxa9 does not have any ability to promote myeloid proliferation. The Pbx-independence of Nup98-HoxA9 is consistent with the observation that other Nup98 fusion proteins found in human AML, such as Nup98-HoxD13 (Raza-Egilmez et al., 1998), Nup98-PMX1 , Nup98-HoxA11 (Fujino et al., 2002) , and Nup98-HoxA13 (Fujino et al., 2002 ) lack a Pbx-interaction motif. These proteins may employ the same transcriptional mechanism of myeloid immortalization as does Nup98-HoxA9, and it will be important to determine whether they, too, maintain expression of Hoxa9, Hoxa7 and Meis1.
Although this study is the first to demonstrate that a single human myeloid oncoprotein maintains transcription of Meis1 and Hox proto-oncogenes, the correlation between Mll-containing oncoproteins and coexpressed Hoxa9 and Meis1 -even in lymphoid leukaemias (Rozovskaia et al., 2001) -suggests that MLL oncoproteins may also enforce Hox and Meis1 gene expression in immortalized progenitors. Understanding the genetic basis by which Hox proteins regulate proliferation and differentiation of normal haematopoietic progenitors, therefore, remains an important goal that should provide insight into the development of acute leukaemias, as well as provide targets for the treatment of AML.
Materials and methods
Construction of recombinant plasmids and retroviral vectors
cDNA's encoding Nup98-HoxA9 were subcloned into the polylinker of the Murine Stem Cell proviral vector, MSCVneo. Helper-free virus was produced by cotransfection of 293T cells with MSCV vectors and a packaging-deficient MLV provirus (Calvo et al., 2000) , and used for infection of primary murine marrow.
Marrow infections
Primary marrow was isolated from the femurs and tibias of Balb/c mice and progenitors separated from mature phagocytic and lymphocytic cells on Ficoll-Paque gradients, followed by negative selection by depletion of lineage positive cells (Stem Cell Technologies). Ten thousand progenitors were transferred to each well of fibronectin-coated 24-well tissue culture plates, incubated with 1 ml of helper-free retrovirus containing 5610 5 G418-resistance units, and 1 ml of Marrow Culture Medium (MCM; RPMI 1640, 10% FBS, 16antibiotics (Penicillin, Streptomycin), 16glutamine, 1 ng/ ml of IL-3 or 16 units/ml of GM -CSF) containing LipofectAmine (Gibco -BRL) at a concentration of 1 ml per ml. Cells were spun at 2500 g at 228C for 1 h, incubated under conditions of 378C/5% CO 2 , and cultured in MCM medium thereafter. Non-adherent cells were transferred every 7 days to new plates.
Antiserum and immunoblots
Antiserum against the carboxyl terminal HD of Hoxa9 and against the Meis1a HD and C-terminus (Gly261-Arg340) were described previously (Calvo et al., 2000 (Calvo et al., , 2001 . For antiHoxa9 immunoblots, protein extract from 5610 4 cells boiled in Laemmli sample buffer were resolved by SDS -PAGE through 12.5% gels, transferred to a PVDF membrane, detected using polyclonal Hoxa9 antisera (Upstate Biotechnology) at a 1:1000 dilution, and visualized using a chemiluminescent Phototope-HRP Detection Kit (New England Biolabs). In the case of anti-Meis1 immunoblots, nuclear extract derived from 5610 5 cells were analysed per lane, as described above.
Northern blots
Cytoplasmic RNA was purified from myeloid progenitors (RNEasy, Qiagen). Fifteen mg of cytoplasmic RNA was resolved by formaldehyde-agarose gel electrophoresis and transferred to a positively-charged nylon membrane (GeneScreen Plus, NEN).
32 P-dCTP-labelled DNA probes were prepared from 100 ng of DNA, using random hexamer oligolabelling (Pharmacia). Hybridization in Ultrahyb (Ambion) and washing were carried out at 48C according to manufacturers' protocols. Probes were obtained from sources as described previously (Calvo et al., 2000) .
Electrophoretic mobility shift assays (EMSA)
Oligonucleotides containing a consensus binding site for the Pbx-Hoxa9 heterodimer (bolded in tcacgg TGATTTATgagcgactgctcgg) were synthesized (Genosys Biotechnologies, Inc., The Woodland, TX, USA) and labelled with 32 P-ATP as described (Calvo et al., 2000) .
Myeloid differentiation assays
10
5 myeloid progenitors per sample were washed twice in PBS to remove cytokine from the medium. Cells were resuspended in RPMI 1640, 10% FBS, 1% Pen/Strep with addition of the appropriate cytokine (0.5 ng/ml of G-CSF; 10 ng/ml M-CSF; 1 ng/ml IL-3, 1:200 dilution of SCFcontaining supernate). Neutrophil differentiation was examined by Wright -Giemsa staining following 72 h of culture in G-CSF, and macrophage differentiation following 8 days of culture in M-CSF.
